Risk factors

Cerus (CERS) risk factors

Item 1A of every Cerus Corp. 10-K on file, and what changed from one year to the next.

Open CERS in Gloomberb →
  • FY2025 10-K risk factors

    43 risks, 7 new, 8 dropped, 10 reworded since the prior year. Regulatory setbacks hit European approval for the red blood cell system via CBG application closure.

    Filed Mar 02, 2026
  • FY2024 10-K risk factors

    44 risks. Cerus is commercializing the INTERCEPT Blood System amid concentration risks and stringent global healthcare regulations. The company relies heavily on third-party manufacturers, government contracts like BARDA, and achieving broader market adoption. Sustaining profitability and financing ongoing clinical developments remain central financial challenges.

    Filed Feb 26, 2025